Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results.

Turner JA, Saunders K, Shortreed SM, Rapp SE, Thielke S, LeResche L, Riddell KM, Von Korff M.

J Gen Intern Med. 2014 Feb;29(2):305-11. doi: 10.1007/s11606-013-2651-6. Epub 2013 Oct 19.

2.

Chronic opioid therapy urine drug testing in primary care: prevalence and predictors of aberrant results.

Turner JA, Saunders K, Shortreed SM, LeResche L, Riddell K, Rapp SE, Von Korff M.

J Gen Intern Med. 2014 Dec;29(12):1663-71. doi: 10.1007/s11606-014-3010-y. Epub 2014 Sep 13.

3.

Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy.

Morasco BJ, Krebs EE, Cavanagh R, Hyde S, Crain A, Dobscha SK.

J Opioid Manag. 2015 Jan-Feb;11(1):45-51. doi: 10.5055/jom.2015.0251.

PMID:
25750164
4.

Capsule commentary on Turner et al., chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results.

Rich BA.

J Gen Intern Med. 2014 Feb;29(2):358. doi: 10.1007/s11606-013-2675-y. No abstract available.

5.

Predictors of urine drug testing for patients with chronic pain: Results from a national cohort of U.S. veterans.

Morasco BJ, Peters D, Krebs EE, Kovas AE, Hart K, Dobscha SK.

Subst Abus. 2016;37(1):82-7. doi: 10.1080/08897077.2015.1110742. Epub 2015 Oct 30.

PMID:
26516794
6.

Prescription opioid abuse and misuse: gap between primary-care investigator assessment and actual extent of these behaviors among patients with chronic pain.

Setnik B, Roland CL, Pixton GC, Sommerville KW.

Postgrad Med. 2017 Jan;129(1):5-11. doi: 10.1080/00325481.2017.1245585. Epub 2016 Oct 26.

PMID:
27782769
7.

Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified.

Wyse JJ, Morasco BJ, Dobscha SK, Demidenko MI, Meath THA, Lovejoy TI.

J Opioid Manag. 2018 Jul/Aug;14(4):295-303. doi: 10.5055/jom.2018.0461.

PMID:
30234926
8.

A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.

McCarberg BH.

Postgrad Med. 2011 Nov;123(6):124-31. doi: 10.3810/pgm.2011.11.2502. Review.

PMID:
22104461
9.

Frequency, predictors, and outcomes of urine drug testing among patients with advanced cancer on chronic opioid therapy at an outpatient supportive care clinic.

Arthur JA, Edwards T, Lu Z, Reddy S, Hui D, Wu J, Liu D, Williams JL, Bruera E.

Cancer. 2016 Dec 1;122(23):3732-3739. doi: 10.1002/cncr.30240. Epub 2016 Aug 10.

10.

Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test.

Nugent SM, Dobscha SK, Morasco BJ, Demidenko MI, Meath THA, Frank JW, Lovejoy TI.

J Gen Intern Med. 2017 Oct;32(10):1076-1082. doi: 10.1007/s11606-017-4084-0. Epub 2017 Jun 9.

11.

Prevalence of prescription opioid use disorder among chronic opioid therapy patients after health plan opioid dose and risk reduction initiatives.

Von Korff M, Walker RL, Saunders K, Shortreed SM, Thakral M, Parchman M, Hansen RN, Ludman E, Sherman KJ, Dublin S.

Int J Drug Policy. 2017 Aug;46:90-98. doi: 10.1016/j.drugpo.2017.05.053. Epub 2017 Jun 27.

PMID:
28666143
12.

Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests.

Bagley SM, Cheng DM, Winter M, Alford DP, LaBelle C, Walley AY, Samet JH.

Drug Alcohol Depend. 2018 Nov 1;192:245-249. doi: 10.1016/j.drugalcdep.2018.08.010. Epub 2018 Sep 25.

PMID:
30290291
13.

Urine drug testing in chronic pain.

Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, Jordan AE, Colson J.

Pain Physician. 2011 Mar-Apr;14(2):123-43. Review.

14.
15.

Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.

McCarberg BH.

Postgrad Med. 2011 Nov;123(6):132-9. doi: 10.3810/pgm.2011.11.2503. Review.

PMID:
22104462
16.

American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.

Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJ, Fellows B, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm S 2nd, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW; American Society of Interventional Pain Physicians.

Pain Physician. 2012 Jul;15(3 Suppl):S67-116.

17.

Correlates of opiate misuse based on aberrant urine drug tests for patients on chronic opiate therapy in a safety-net, academic primary care clinic.

Bakhai S, Thilagar B, Reynolds JL, Leonard KE.

J Opioid Manag. 2018 Jan/Feb;14(1):23-33. doi: 10.5055/jom.2018.0426.

PMID:
29508893
18.

Retrospective review of physician opioid prescribing practices in patients with aberrant behaviors.

Gupta A, Patton C, Diskina D, Cheatle M.

Pain Physician. 2011 Jul-Aug;14(4):383-9.

19.

Correlates of prescription opioid initiation and long-term opioid use in veterans with persistent pain.

Dobscha SK, Morasco BJ, Duckart JP, Macey T, Deyo RA.

Clin J Pain. 2013 Feb;29(2):102-8. doi: 10.1097/AJP.0b013e3182490bdb.

20.

Clinician Response to Aberrant Urine Drug Test Results of Patients Prescribed Opioid Therapy for Chronic Pain.

Morasco BJ, Krebs EE, Adams MH, Hyde S, Zamudio J, Dobscha SK.

Clin J Pain. 2019 Jan;35(1):1-6. doi: 10.1097/AJP.0000000000000652.

PMID:
30222612

Supplemental Content

Support Center